Mesoblast Limited

(NASDAQ:MESO)

Latest On Mesoblast Limited (MESO):

Date/Time Type Description Signal Details
2023-05-26 06:19 ESTNewsMesoblast Limited (MESO) Q3 2023 Earnings Call TranscriptN/A
2023-05-26 06:19 ESTNewsMesoblast GAAP EPS of -$0.025 beats by $0.13, revenue of $1.94M misses by $0.18MN/A
2023-05-04 20:51 ESTNewsMesoblast Has A Strong Upside PotentialN/A
2023-03-08 20:50 ESTNewsMesoblast stock surges ~10% on getting FDA review of graft versus host disease therapyN/A
2023-03-02 11:37 ESTNewsMesoblast Limited. (MESO) Q2 2023 Earnings Call TranscriptN/A
2023-02-28 14:47 ESTNewsMesoblast Limited 2023 Q2 - Results - Earnings Call PresentationN/A
2022-12-23 19:10 ESTNewsMesoblast and Oaktree extend availability of undrawn facilityN/A
2022-12-06 13:18 ESTNewsMesoblast stock falls 10% as Jefferies cuts rating to HoldN/A
2022-11-24 00:38 ESTNewsMesoblast Limited (MESO) Q1 2023 Earnings Call TranscriptN/A
2022-11-23 07:29 ESTNewsMesoblast GAAP EPS of -$0.0243 beats by $0.14, revenue of $1.5M misses by $1.82MN/A
2022-10-31 12:34 ESTNewsMesoblast reports operational and financial highlights for Q3N/A
2022-08-31 07:31 ESTNewsMesoblast Limited 2022 Q4 - Results - Earnings Call PresentationN/A
2022-08-31 07:31 ESTNewsMesoblast Limited (MESO) Q4 2022 Earnings Call TranscriptN/A
2022-08-31 07:31 ESTNewsMesoblast GAAP EPS of -$0.14, revenue of $10.21MN/A
2022-06-01 09:26 ESTNewsMesoblast GAAP EPS of -$0.03, revenue of $2MN/A
2022-02-02 13:18 ESTNewsNew medical chief at MesoblastN/A
2022-01-12 16:28 ESTNewsMesoblast’s rexlemestrocel-L results in durable pain reduction in degenerative disc diseaseN/A
2021-12-31 16:22 ESTNewsMesoblast to provide new data to FDA to support remestemcel-L BLA resubmissionN/A
2021-12-16 20:12 ESTNewsFDA’s OTAT in agreement pain reduction as primary endpoint in Mesoblast's Phase 3 programN/A
2021-12-14 07:58 ESTNewsMesoblast falls 8% after Novartis terminates deal prior to closingN/A
2021-12-06 08:59 ESTNewsMesoblast's rexlemestrocel-L shows treatment benefit in cardiovascular events in heart patientsN/A
2021-11-24 11:49 ESTNewsMesoblast EPS beats by $0.10, beats on revenueN/A
2021-11-22 16:32 ESTNewsMesoblast and Oaktree Capital refinance senior debt facilityN/A
2021-11-15 18:27 ESTNewsMesoblast's rexlemestrocel-l shows reduction in cardiovascular mortality, heart attacks and strokesN/A
2021-08-31 00:59 ESTNewsMesoblast EPS beats by $0.38N/A
2021-07-22 15:51 ESTNewsMesoblast reports FQ3 resultsN/A
2021-07-22 15:48 ESTNewsMesoblast provides update on rexlemestrocel-L in development for low back painN/A
2021-07-22 15:47 ESTNewsMesoblast reports respiratory function results of COVID-19 ARDS trialN/A
2021-07-22 15:47 ESTNewsMesoblast presents data showing mortality reduction of COVID-19 therapyN/A
2021-05-01 01:30 ESTNewsMESO, MOTS and SALM among premarket gainersN/A
2021-04-30 03:28 ESTNewsMesoblast's remestemcel-L reduces mortality by 46% in patients under age 65 with COVID-19 ARDSN/A
2021-04-08 03:05 ESTNewsMaxim upgrades Mesoblast to buy, sets $18 price targetN/A
2021-03-17 15:22 ESTAnalyst RatingThe Analyst Target Price has decreased from $14.5 to $13.7.Neutral
2021-03-16 23:50 ESTAnalyst RatingThe Analyst Target Price has decreased from $14.96 to $14.5.Neutral
2021-03-03 00:44 ESTNewsMesoblast announces a private placement of $110 millionN/A
2021-03-01 01:44 ESTEarnings EstimateAn EPS average of $0.03 is estimated for the quarter ending on March 31, 2021.Buy
2021-02-28 05:42 ESTFinancialsCompany financials have been released.Neutral
2021-02-17 14:54 ESTNewsMesoblast gains as remestemcel-l shows positive action in MIS-C post COVID-19N/A
2021-02-15 13:38 ESTAnalyst RatingThe Analyst Target Price has increased from $14.29 to $14.96.Buy
2021-02-12 12:18 ESTNewsMesoblast announces data from Phase 3 study in chronic back painN/A
2021-01-29 11:38 ESTNewsMesoblast issues FQ2 operational and financial updateN/A
2021-01-27 14:09 ESTAnalyst RatingThe Analyst Target Price has decreased from $14.96 to $14.29.Neutral
2021-01-19 22:20 ESTNewsMesoblast's Time May Be UpN/A
2021-01-11 12:34 ESTNewsMesoblast's rexlemestrocel-l reduces heart attacks, strokesN/A
2020-12-25 10:33 ESTAnalyst RatingThe Analyst Target Price has decreased from $16.45 to $14.96.Neutral
2020-12-24 16:56 ESTNewsMesoblast: The Future Looks BleakN/A
2020-12-24 02:40 ESTAnalyst RatingThe Analyst Target Price has increased from $14.96 to $16.45.Buy
2020-12-23 18:45 ESTAnalyst RatingThe Analyst Target Price has decreased from $15.39 to $14.96.Neutral
2020-12-20 22:34 ESTAnalyst RatingThe Analyst Target Price has decreased from $16.82 to $15.39.Neutral
2020-12-18 05:21 ESTNewsMesoblast shares plunge 32% after stem-cell therapy not likely to meet target for reducing mortality due to COVID-19N/A

About Mesoblast Limited (MESO):

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.

MESO Quotes by TradingView

See Advanced Chart

General

  • Name Mesoblast Limited
  • Symbol MESO
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 102
  • Fiscal Year EndJune
  • IPO Date2015-11-13
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.mesoblast.com
View More

Valuation

  • Forward PE 454.55
  • Price/Sales (Trailing 12 Mt.) 62.46
  • Price/Book (Most Recent Quarter) 2.28
  • Enterprise Value Revenue 70.47
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.29
  • Next Year EPS Estimate $0.17
  • Operating Margin -682%
  • Return on Assets -10%
  • Return on Equity -19%
  • Revenue 16.45 million
  • Earnings Per Share -$0.91
  • Revenue Per Share $0.15
  • Gross Profit 6.85 million
  • Quarterly Earnings Growth 1.6%
View More

Highlights

  • Market Capitalization 1.26 billion
  • EBITDA -78815000
  • Analyst Target Price $13.7
  • Book Value Per Share $4.42
View More

Share Statistics

  • Shares Outstanding 129.62 million
  • Shares Float 101.69 million
  • % Held by Insiders <1%
  • % Held by Institutions 2.87%
  • Shares Short 1.88 million
  • Shares Short Prior Month 2.82 million
  • Short Ratio 4.29
  • Short % of Shares Outstanding 2%
View More

Technicals

  • Beta 2.71
  • 52 Week High $21.28
  • 52 Week Low $3.12
  • 50 Day Moving Average 9.64
  • 200 Day Moving Average 12.23
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Mesoblast Limited (MESO) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Mesoblast Limited (MESO) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-26$N/A-$0.22-$0.15-43.61%
2020-09-302020-11-19$N/A-$0.21-$0.2619.04%
2020-06-302020-08-26$N/A-$0.30-$0.21-42.52%
2020-03-312020-05-27$12.08 million-$0.14-$0.1612.62%
2019-12-312020-02-26$2.21 million-$0.23-$0.13-71.64%
2019-09-302019-11-25$16.87 million-$0.06-$0.1970.27%
2019-06-302019-08-29$1.25 million-$0.21-$0.2724.04%
2019-03-312019-05-30$1.25 million-$0.25-$0.263.85%
2018-12-312019-02-20$1.87 million-$0.25-$0.23-8.7%
2018-09-302018-11-15$11.64 million-$0.20-$0.2311.52%
2018-06-302018-08-29$1.7 million-$0.22-$0.232.19%
2018-03-312018-05-30$1.07 million-$0.22-$0.22-1.59%
2017-12-312018-02-27$13.28 million$0.15-$0.20172.03%
2017-09-302017-11-14$1.11 million-$0.08-$0.2467.21%
2017-06-302017-08-29$473000-$0.32-$0.21-50.59%
2017-03-312017-05-24$820000-$0.12-$0.1935.26%
2016-12-312017-02-26$433000-$0.26-$0.20-34.92%
2016-09-302016-11-14$218000-$0.05-$0.2175.05%
2016-06-302016-08-24$26.62 million$0.64-$0.20423.54%
2016-03-312016-05-09$3.85 million-$0.04-$0.1263.7%
2015-12-312016-02-16$3.75 million-$0.31-$0.17-80.75%
2015-09-302015-12-16$7.25 million-$0.19

Mesoblast Limited (MESO) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Mesoblast Limited (MESO) Chart:

MESO chart by TradingView

Mesoblast Limited (MESO) News:

Below you will find a list of latest news for Mesoblast Limited (MESO) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Mesoblast Limited (MESO) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2026-01-160.50CALL0 200TRUE00
2026-01-1610CALL0 100TRUE00
2026-01-161.50CALL0 00TRUE00
2026-01-1620CALL0 1000TRUE00
2026-01-162.50CALL0 12610TRUE00
2026-01-1630CALL0 00TRUE00
2026-01-1640CALL0 100TRUE00
2026-01-1658CALL0 0372.78TRUE00
2026-01-16610.4CALL0 1322.04TRUE00
2026-01-16712.3CALL0 342279.65TRUE00
2026-01-1687.84CALL0 0243.22TRUE00
2026-01-1690CALL0 0211.21TRUE00
2026-01-16105.8CALL0 150182.59TRUE00
2026-01-16115.95CALL0 18156.64TRUE00
2026-01-16125.93CALL0 565132.82TRUE00
2026-01-16137.26CALL0 148110.68TRUE00
2026-01-16144.49CALL0 730TRUE00
2026-01-16153.65CALL0 8540TRUE00
2026-01-16162.87CALL0 79850.84TRUE00
2026-01-16171.75CALL45 83879.89TRUE1.750
2026-01-16181.85CALL0 813203.96TRUE00
2026-01-16191.23CALL0 1155200.72FALSE00
2026-01-16201.25CALL0 1914123FALSE00
2026-01-16210.25CALL10 59078.11FALSE0.250
2026-01-16220.7CALL0 1665171.27FALSE00
2026-01-16231.1CALL0 1279258.69FALSE00
2026-01-16240.2CALL0 2018275.56FALSE00
2026-01-16250.15CALL0 929505.36FALSE00
2026-01-16300.5CALL0 243579.22FALSE00
2026-01-16350.45CALL0 15630.72FALSE00
2026-01-160.50PUT0 0343.62FALSE00
2026-01-1610PUT0 0236.05FALSE00
2026-01-161.50PUT0 0189.92FALSE00
2026-01-1620PUT0 20161.02FALSE00
2026-01-162.50PUT0 0158.33FALSE00
2026-01-1630PUT0 0474.13FALSE00
2026-01-1640PUT0 0153.53FALSE00
2026-01-1650PUT0 0341.86FALSE00
2026-01-1660PUT0 00FALSE00
2026-01-1670.8PUT0 31407.95FALSE00
2026-01-1681.2PUT0 71199.53FALSE00
2026-01-1690.93PUT0 221048.04FALSE00
2026-01-16101.22PUT0 63928.59FALSE00
2026-01-16112.85PUT0 3829.64FALSE00
2026-01-16121.5PUT0 30393.2FALSE00
2026-01-16132.6PUT0 11670.33FALSE00
2026-01-16140.8PUT0 122214.68FALSE00
2026-01-16150.3PUT0 469211.4FALSE00
2026-01-16162.92PUT0 27486.06FALSE00
2026-01-16170.5PUT0 190256.34FALSE00
2026-01-16181PUT0 32202.59FALSE00
2026-01-16191.15PUT0 46129.91TRUE00
2026-01-16202.2PUT0 92114.01TRUE00
2026-01-16210PUT0 096.46TRUE00
2026-01-16220PUT0 0113.19TRUE00
2026-01-16230PUT0 0104.95TRUE00
2026-01-16240PUT0 00TRUE00
2026-01-162510.8PUT0 50TRUE00
2026-01-16300PUT0 00TRUE00
2026-01-16350PUT0 00TRUE00
2026-02-20130CALL0 085.44TRUE00
2026-02-20140CALL0 084.75TRUE00
2026-02-20150CALL0 069.56TRUE00
2026-02-20160CALL0 078.59TRUE00
2026-02-20170CALL0 081.91TRUE00
2026-02-20180CALL0 0101.15TRUE00
2026-02-20190CALL0 0116.86FALSE00
2026-02-20200.6CALL0 7132.27FALSE00
2026-02-20210CALL0 0104.03FALSE00
2026-02-20220CALL0 0149.23FALSE00
2026-02-20230CALL0 0248.91FALSE00
2026-02-20240CALL0 0257.83FALSE00
2026-02-20250CALL0 0266.13FALSE00
2026-02-20300CALL0 0300.79FALSE00
2026-02-20350CALL0 0327.64FALSE00
2026-02-20130PUT0 0350.32FALSE00
2026-02-20140PUT0 0315.5FALSE00
2026-02-20150PUT0 0283.75FALSE00
2026-02-20160PUT0 0254.35FALSE00
2026-02-20171.2PUT10 069.07FALSE1.20
2026-02-20181.6PUT0 176.51FALSE00
2026-02-20192.5PUT0 1686.08TRUE00
2026-02-20203.2PUT0 882.51TRUE00
2026-02-20210PUT0 078.29TRUE00
2026-02-20220PUT0 084.17TRUE00
2026-02-20230PUT0 079.52TRUE00
2026-02-20240PUT0 076.94TRUE00
2026-02-20250PUT0 083.89TRUE00
2026-02-20300PUT0 098.12TRUE00
2026-02-20350PUT0 00TRUE00
2026-04-1730CALL0 0173.1TRUE00
2026-04-1750CALL0 0116.83TRUE00
2026-04-17810.3CALL0 261.79TRUE00
2026-04-1799.75CALL0 469.08TRUE00
2026-04-17105.8CALL0 20866.93TRUE00
2026-04-17110CALL0 086.23TRUE00
2026-04-17126.36CALL0 24757.18TRUE00
2026-04-17135.1CALL0 1983.92TRUE00
2026-04-17146.4CALL0 82577.3TRUE00
2026-04-17155.4CALL0 6880.11TRUE00
2026-04-17165.3CALL0 35679.09TRUE00
2026-04-17173.5CALL0 32079.4TRUE00
2026-04-17183.8CALL0 56970.21TRUE00
2026-04-17194.3CALL0 65180.97FALSE00
2026-04-17203.22CALL0 139474.68FALSE00
2026-04-17212.26CALL0 257390.61FALSE00
2026-04-17251.42CALL0 3816124.24FALSE00
2026-04-17300.8CALL0 462126.01FALSE00
2026-04-17350.5CALL0 1054221.96FALSE00
2026-04-1730PUT0 00FALSE00
2026-04-1750PUT0 00FALSE00
2026-04-1780PUT0 0427.81FALSE00
2026-04-1790PUT0 0373.77FALSE00
2026-04-17101.7PUT0 0331.24FALSE00
2026-04-17111.85PUT0 13296.06FALSE00
2026-04-17122.2PUT0 15265.95FALSE00
2026-04-17132.4PUT0 54239.51FALSE00
2026-04-17143.2PUT0 11215.82FALSE00
2026-04-17151.5PUT0 11199.63FALSE00
2026-04-17162PUT0 588.48FALSE00
2026-04-17172.3PUT0 185.63FALSE00
2026-04-17182.95PUT10 10281.7FALSE0.150.05
2026-04-17193.3PUT0 2657.89TRUE00
2026-04-17203.6PUT0 1083.56TRUE00
2026-04-17210PUT0 067.07TRUE00
2026-04-17257.9PUT1 181.14TRUE7.90
2026-04-17300PUT0 080.41TRUE00
2026-04-17350PUT0 094.22TRUE00
2026-07-1730CALL0 0116.15TRUE00
2026-07-1750CALL0 00TRUE00
2026-07-17100CALL0 076.62TRUE00
2026-07-17110CALL0 070.68TRUE00
2026-07-17127.1CALL0 176.81TRUE00
2026-07-17136.9CALL0 378.23TRUE00
2026-07-17146.3CALL0 479.34TRUE00
2026-07-17155.61CALL0 980.31TRUE00
2026-07-17165.7CALL0 1479.09TRUE00
2026-07-17175.52CALL0 30580.24TRUE00
2026-07-17184.3CALL0 777.52TRUE00
2026-07-17193.9CALL0 176.19FALSE00
2026-07-17204.4CALL0 6279.03FALSE00
2026-07-17213.4CALL0 4286.9FALSE00
2026-07-17223.4CALL0 6773.38FALSE00
2026-07-17233.1CALL0 580.2FALSE00
2026-07-17243CALL0 183.77FALSE00
2026-07-17252.65CALL0 174386.04FALSE00
2026-07-17300CALL0 0147.95FALSE00
2026-07-17350CALL0 0161.36FALSE00
2026-07-1730PUT0 00FALSE00
2026-07-1750PUT0 00FALSE00
2026-07-17100PUT0 0243.94FALSE00
2026-07-17110PUT0 0218.11FALSE00
2026-07-17120PUT0 0196.03FALSE00
2026-07-17130PUT0 0176.65FALSE00
2026-07-17142.2PUT0 1109.61FALSE00
2026-07-17152.65PUT0 1110.62FALSE00
2026-07-17163.2PUT0 1109.14FALSE00
2026-07-17170PUT0 085.55FALSE00
2026-07-17180PUT0 083.9FALSE00
2026-07-17190PUT0 082.64TRUE00
2026-07-17200PUT0 081.77TRUE00
2026-07-17210PUT0 085.09TRUE00
2026-07-17220PUT0 085.96TRUE00
2026-07-17230PUT0 084.47TRUE00
2026-07-17240PUT0 084.44TRUE00
2026-07-17250PUT0 083.03TRUE00
2026-07-17300PUT0 080.15TRUE00
2026-07-17350PUT0 080.9TRUE00
2027-01-1530CALL0 00TRUE00
2027-01-1550CALL0 00TRUE00
2027-01-1588.5CALL0 244.18TRUE00
2027-01-15106.9CALL0 26655.79TRUE00
2027-01-15128.74CALL0 1066.05TRUE00
2027-01-15130CALL0 00TRUE00
2027-01-15154.6CALL0 2268.32TRUE00
2027-01-15176.5CALL0 44971.07TRUE00
2027-01-15203.6CALL0 14985.63FALSE00
2027-01-15225CALL0 8069.08FALSE00
2027-01-15252.9CALL0 7372.24FALSE00
2027-01-15273.21CALL0 49570.94FALSE00
2027-01-15302.8CALL0 52105.3FALSE00
2027-01-15350CALL0 0115.02FALSE00
2027-01-1530PUT0 00FALSE00
2027-01-1550PUT0 00FALSE00
2027-01-1580PUT0 0230.08FALSE00
2027-01-15102.35PUT0 2163.83FALSE00
2027-01-15120PUT0 0143.45FALSE00
2027-01-15130PUT0 00FALSE00
2027-01-15150PUT0 079.38FALSE00
2027-01-15170PUT0 085.06FALSE00
2027-01-15207.6PUT0 285.93TRUE00
2027-01-15220PUT0 080.33TRUE00
2027-01-15250PUT0 084.16TRUE00
2027-01-15270PUT0 083.37TRUE00
2027-01-15300PUT0 084.35TRUE00
2027-01-15350PUT0 080.69TRUE00
2028-01-2130CALL0 00TRUE00
2028-01-2150CALL0 00TRUE00
2028-01-21811.51CALL1 261.99TRUE11.510
2028-01-211011CALL0 1556.58TRUE00
2028-01-21129CALL0 159.01TRUE00
2028-01-21150CALL0 064.26TRUE00
2028-01-21177.5CALL11 120467.19TRUE00
2028-01-21206.6CALL7 86567.59FALSE00
2028-01-21226.1CALL107 48867.96FALSE-0.1-0.02
2028-01-21255.5CALL161 16168.92FALSE-0.1-0.02
2028-01-21275.1CALL178 110968.95FALSE00
2028-01-21304.6CALL57 79769.25FALSE00
2028-01-21354CALL312 75870.49FALSE00
2028-01-2130PUT0 00FALSE00
2028-01-2150PUT0 00FALSE00
2028-01-2180PUT0 0168.45FALSE00
2028-01-21102.44PUT0 6378.28FALSE00
2028-01-21123.33PUT0 2969.52FALSE00
2028-01-21156.1PUT0 2084.64FALSE00
2028-01-21170PUT0 081.12FALSE00
2028-01-21209PUT0 1080.75TRUE00
2028-01-212211PUT0 1081.52TRUE00
2028-01-212512.2PUT0 2084.2TRUE00
2028-01-21270PUT0 083.66TRUE00
2028-01-21300PUT0 084.76TRUE00
2028-01-21350PUT0 083.39TRUE00
2030-12-18100.2CALL456 3400TRUE-3.3-0.94
2030-12-18250PUT 0TRUE00

Latest MESO Trades:

Date Shares Price
Jun 13, 2022 7:54 PM EST100$2.645
Jun 13, 2022 7:54 PM EST100$2.645
Jun 13, 2022 7:55 PM EST100$2.64
Jun 13, 2022 7:57 PM EST186$2.66
Jun 13, 2022 7:57 PM EST14$2.66

Mesoblast Limited (MESO) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020031530/0001564590-20-031530-index.htm
2020-01-30SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1345099/000119312520019148/0001193125-20-019148-index.htm
2020-07-27S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1345099/000121390020018628/0001213900-20-018628-index.htm
2020-05-26DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1345099/000134509920000001/0001345099-20-000001-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1345099/000142284920000077/0001422849-20-000077-index.htm
2019-09-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019034209/0001564590-19-034209-index.htm
2019-09-0920-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1345099/000156459019034304/0001564590-19-034304-index.htm
2019-09-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019034483/0001564590-19-034483-index.htm
2019-10-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019036315/0001564590-19-036315-index.htm
2019-10-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019036431/0001564590-19-036431-index.htm
2019-10-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019036737/0001564590-19-036737-index.htm
2019-10-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019037256/0001564590-19-037256-index.htm
2019-11-016-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019039260/0001564590-19-039260-index.htm
2019-11-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019041204/0001564590-19-041204-index.htm
2019-11-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019044600/0001564590-19-044600-index.htm
2019-11-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019044601/0001564590-19-044601-index.htm
2019-11-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019044825/0001564590-19-044825-index.htm
2019-12-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019045775/0001564590-19-045775-index.htm
2019-12-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019046754/0001564590-19-046754-index.htm
2020-01-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020000984/0001564590-20-000984-index.htm
2020-01-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020001658/0001564590-20-001658-index.htm
2020-02-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020003090/0001564590-20-003090-index.htm
2020-02-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020003512/0001564590-20-003512-index.htm
2020-02-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020004688/0001564590-20-004688-index.htm
2020-02-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020006501/0001564590-20-006501-index.htm
2020-02-286-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020007597/0001564590-20-007597-index.htm
2020-03-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020009861/0001564590-20-009861-index.htm
2020-03-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020011865/0001564590-20-011865-index.htm
2020-03-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020012613/0001564590-20-012613-index.htm
2020-04-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020014830/0001564590-20-014830-index.htm
2020-04-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020015584/0001564590-20-015584-index.htm
2020-04-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020016005/0001564590-20-016005-index.htm
2020-04-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020017344/0001564590-20-017344-index.htm
2020-04-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020018322/0001564590-20-018322-index.htm
2020-05-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020020611/0001564590-20-020611-index.htm
2020-05-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020022226/0001564590-20-022226-index.htm
2020-05-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020025586/0001564590-20-025586-index.htm
2020-05-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020026055/0001564590-20-026055-index.htm
2020-05-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020026914/0001564590-20-026914-index.htm
2020-05-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020027408/0001564590-20-027408-index.htm
2020-05-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020027410/0001564590-20-027410-index.htm
2020-06-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020028116/0001564590-20-028116-index.htm
2020-06-186-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020029698/0001564590-20-029698-index.htm
2020-06-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020030668/0001564590-20-030668-index.htm
2020-07-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020031530/0001564590-20-031530-index.htm
2020-07-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020031863/0001564590-20-031863-index.htm
2020-07-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020032147/0001564590-20-032147-index.htm
2020-07-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020033456/0001564590-20-033456-index.htm
2020-08-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020035263/0001564590-20-035263-index.htm
2020-08-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020038657/0001564590-20-038657-index.htm
2020-08-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020039445/0001564590-20-039445-index.htm
2020-08-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020040358/0001564590-20-040358-index.htm
2020-08-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020041082/0001564590-20-041082-index.htm
2020-08-316-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020041869/0001564590-20-041869-index.htm
2020-09-0320-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1345099/000156459020042401/0001564590-20-042401-index.htm
2020-09-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020042407/0001564590-20-042407-index.htm
2020-09-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020042713/0001564590-20-042713-index.htm
2020-09-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020043641/0001564590-20-043641-index.htm
2020-09-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020043751/0001564590-20-043751-index.htm
2020-10-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020045777/0001564590-20-045777-index.htm
2020-10-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020046432/0001564590-20-046432-index.htm
2020-10-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020047335/0001564590-20-047335-index.htm
2020-10-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020048488/0001564590-20-048488-index.htm
2020-11-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020049709/0001564590-20-049709-index.htm